Total Payments
$78,314
2022 Payments
$6,500
Companies
7
Transactions
114
Medicare Patients
495
Medicare Billing
$47,836
Payment Breakdown by Category
Consulting$58,914 (75.2%)
Travel$8,022 (10.2%)
Other$8,000 (10.2%)
Food & Beverage$2,162 (2.8%)
Research$1,216 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $58,914 | 19 | 75.2% |
| Travel and Lodging | $8,022 | 34 | 10.2% |
| Honoraria | $7,000 | 3 | 8.9% |
| Food and Beverage | $2,162 | 41 | 2.8% |
| Unspecified | $1,216 | 13 | 1.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,000 | 4 | 1.3% |
Payments by Type
General
$77,098
101 transactions
Research
$1,216
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $40,828 | 44 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $22,489 | 36 | $0 (2019) |
| Theratechnologies Inc. | $8,386 | 12 | $0 (2020) |
| Gilead Sciences, Inc. | $3,321 | 15 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $1,600 | 2 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $1,000 | 4 | $0 (2020) |
| GlaxoSmithKline, LLC. | $690.00 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $6,500 | 2 | ViiV Healthcare Company ($6,500) |
| 2021 | $6,210 | 3 | ViiV Healthcare Company ($5,520) |
| 2020 | $15,045 | 8 | ViiV Healthcare Company ($11,695) |
| 2019 | $19,221 | 44 | Merck Sharp & Dohme Corporation ($8,387) |
| 2018 | $25,546 | 46 | ViiV Healthcare Company ($12,089) |
| 2017 | $5,792 | 11 | Merck Sharp & Dohme Corporation ($5,542) |
All Payment Transactions
114 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/05/2022 | ViiV Healthcare Company | DOVATO (Drug) | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| Category: HIV | ||||||
| 03/29/2022 | ViiV Healthcare Company | CABENUVA (Biological) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: HIV | ||||||
| 09/02/2021 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $690.00 | General |
| 08/24/2021 | ViiV Healthcare Company | DOVATO (Drug) | Consulting Fee | Cash or cash equivalent | $2,760.00 | General |
| Category: HIV | ||||||
| 04/20/2021 | ViiV Healthcare Company | DOVATO (Drug) | Consulting Fee | Cash or cash equivalent | $2,760.00 | General |
| Category: HIV | ||||||
| 12/14/2020 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $2,760.00 | General |
| 11/25/2020 | Janssen Pharmaceuticals, Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $250.00 | General |
| 11/17/2020 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $1,575.00 | General |
| 11/12/2020 | Janssen Scientific Affairs, LLC | SYMTUZA (Drug) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 10/06/2020 | Theratechnologies Inc. | — | Honoraria | Cash or cash equivalent | $1,500.00 | General |
| 07/23/2020 | Janssen Scientific Affairs, LLC | SYMTUZA (Drug) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 07/10/2020 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $2,760.00 | General |
| 01/07/2020 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $4,600.00 | General |
| 12/09/2019 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $6.01 | General |
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $458.80 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $213.23 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $50.00 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $41.07 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $36.00 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $35.94 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $22.09 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $20.76 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $20.76 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $15.40 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/06/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $156.67 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | Gilead Sciences, Inc. | $1,216 | 13 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 33 | 49 | $12,054 | $3,693 |
| 2022 | 3 | 70 | 84 | $16,471 | $4,502 |
| 2021 | 7 | 222 | 277 | $46,000 | $15,871 |
| 2020 | 5 | 170 | 265 | $84,056 | $23,770 |
Total Patients
495
Total Services
675
Medicare Billing
$47,836
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 33 | 49 | $12,054 | $3,693 | 30.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 20 | 24 | $8,376 | $2,417 | 28.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 26 | 29 | $7,134 | $1,993 | 27.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 24 | 31 | $961.00 | $92.07 | 9.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 27 | 57 | $16,929 | $4,614 | 27.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 34 | 55 | $13,530 | $4,073 | 30.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 18 | 18 | $8,910 | $2,825 | 31.7% |
| 0001A | Adm sarscov2 30mcg/0.3ml 1st | Office | 2021 | 58 | 61 | $2,928 | $2,270 | 77.5% |
| 0002A | Adm sarscov2 30mcg/0.3ml 2nd | Office | 2021 | 49 | 49 | $2,352 | $1,824 | 77.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 12 | 12 | $576.00 | $189.82 | 33.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 24 | 25 | $775.00 | $75.00 | 9.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 57 | 128 | $38,016 | $10,526 | 27.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 47 | 49 | $24,255 | $7,820 | 32.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 36 | 53 | $13,038 | $2,859 | 21.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 19 | 24 | $5,040 | $1,373 | 27.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 11 | 11 | $3,707 | $1,193 | 32.2% |
About Edgar Overton
Edgar Overton is a Infectious Disease healthcare provider based in Birmingham, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1073539201.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Edgar Overton has received a total of $78,314 in payments from pharmaceutical and medical device companies, with $6,500 received in 2022. These payments were reported across 114 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($58,914).
As a Medicare-enrolled provider, Overton has provided services to 495 Medicare beneficiaries, totaling 675 services with total Medicare billing of $47,836. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Birmingham, AL
- Active Since 07/14/2006
- Last Updated 02/01/2024
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1073539201
Products in Payments
- DELSTRIGO (Drug) $13,900
- DOVATO (Drug) $9,420
- EGRIFTA (Drug) $4,095
- TROGARZO (Drug) $2,791
- CABENUVA (Biological) $2,600
- SYMTUZA (Drug) $1,600
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Birmingham
Sonya Heath
Infectious Disease — Payments: $103,197
Infectious Disease $103,197
John Baddley, Md, MD
Infectious Disease — Payments: $101,314
Infectious Disease $101,314
Christina Muzny
Infectious Disease — Payments: $87,717
Infectious Disease $87,717
Peter Pappas
Infectious Disease — Payments: $73,326
Infectious Disease $73,326
William Geisler, Md, MD
Infectious Disease — Payments: $66,779
Infectious Disease $66,779
Jane Schwebke, Md, MD
Infectious Disease — Payments: $61,136
Infectious Disease $61,136